Advertisement

Advertisement

CH:SDZ Stock Latest News

Sandoz downgraded to Sector Perform from Outperform at RBC Capital

The FlySandoz downgraded to Sector Perform from Outperform at RBC Capital

Sandoz announces partnership agreement with Samsung Bioepis

PremiumThe Fly

Sandoz announces partnership agreement with Samsung Bioepis

12d ago

Sandoz deepens Samsung Bioepis alliance to add up to five new biosimilars

PremiumCompany Announcements

Sandoz deepens Samsung Bioepis alliance to add up to five new biosimilars

12d ago

Sandoz Raises CHF 550 Million in Bonds and Extends USD 2 Billion Credit Line

PremiumCompany Announcements

Sandoz Raises CHF 550 Million in Bonds and Extends USD 2 Billion Credit Line

19d ago

Sandoz reshapes biosimilar and generics leadership to seize upcoming patent cliff

PremiumCompany Announcements

Sandoz reshapes biosimilar and generics leadership to seize upcoming patent cliff

20d ago

Sandoz price target raised to CHF 62 from CHF 55 at Berenberg

PremiumThe FlySandoz price target raised to CHF 62 from CHF 55 at Berenberg

25d ago

Sandoz downgraded to Hold from Buy at Deutsche Bank

The Fly

Sandoz downgraded to Hold from Buy at Deutsche Bank

1M ago

Sandoz downgraded to Equal Weight from Overweight at Barclays

The Fly

Sandoz downgraded to Equal Weight from Overweight at Barclays

1M ago

Sandoz lifts profit, dividend and 2026 outlook on biosimilar-driven growth

PremiumCompany Announcements

Sandoz lifts profit, dividend and 2026 outlook on biosimilar-driven growth

1M ago

Sandoz confirms E.C. granted marketing authorization for Ranluspec

PremiumThe Fly

Sandoz confirms E.C. granted marketing authorization for Ranluspec

1M ago

Sandoz wins EU approval for Ranluspec biosimilar, bolstering ophthalmology push

PremiumCompany Announcements

Sandoz wins EU approval for Ranluspec biosimilar, bolstering ophthalmology push

1M ago

Sandoz receives U.S. FDA approval to expand Enzeevu label

PremiumThe Fly

Sandoz receives U.S. FDA approval to expand Enzeevu label

1M ago

Sandoz Wins Expanded U.S. FDA Label for Enzeevu Retinal Biosimilar

PremiumCompany AnnouncementsSandoz Wins Expanded U.S. FDA Label for Enzeevu Retinal Biosimilar

1M ago

Sandoz upgraded to Buy from Hold at Jefferies

The Fly

Sandoz upgraded to Buy from Hold at Jefferies

2M ago

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

The Fly

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

2M ago

Sandoz price target raised to CHF 55 from CHF 49 at Berenberg

PremiumThe Fly

Sandoz price target raised to CHF 55 from CHF 49 at Berenberg

2M ago

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

PremiumThe Fly

Sandoz price target raised to CHF 63 from CHF 60 at Deutsche Bank

2M ago

Sandoz Wins EU Approval for Ondibta Biosimilar Insulin, Bolstering Diabetes Push

PremiumCompany Announcements

Sandoz Wins EU Approval for Ondibta Biosimilar Insulin, Bolstering Diabetes Push

2M ago

Sandoz Targets ‘Golden Decade’ as Patent Cliff Opens USD 600 Billion Generics and Biosimilars Opportunity

PremiumCompany Announcements

Sandoz Targets ‘Golden Decade’ as Patent Cliff Opens USD 600 Billion Generics and Biosimilars Opportunity

3M ago

Sandoz price target raised to CHF 70 from CHF 55 at Barclays

PremiumThe FlySandoz price target raised to CHF 70 from CHF 55 at Barclays

3M ago

Sandoz initiated with a Neutral at Oddo BHF

The Fly

Sandoz initiated with a Neutral at Oddo BHF

3M ago

Sandoz Strengthens Biosimilars Leadership with Key Acquisition

Company Announcements

Sandoz Strengthens Biosimilars Leadership with Key Acquisition

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >